Back to top

Buy Rating on Danaher: Strong Biotech Performance and Growth Potential Despite Market Challenges

Danaher (DHR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on April 23. Analyst Puneet Souda from Leeri...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Danaher Corporation (DHR)